Investor Presentaiton slide image

Investor Presentaiton

Q3 2023 Late-Stage Drug Development Clinical Trials Update Oncology Opdivo Hematology iberdomide Cell Therapy Immunology Cardiovascular Breyanzi cendakimab milvexian Opdualag mezigdomide Abecma LPA1 antagonist Camzyos repotrectinib Reblozyl ll Bristol Myers Squibb Q3 2023 Results Onureg alnuctamab Sotyktu Zeposia obexelimab Not for Product Promotional Use 31
View entire presentation